Allard Soto Raúl
Departamento de Ciencias Jurídicas, Universidad de La Frontera, Temuco, Chile.
Salud Colect. 2015 Mar;11(1):9-21. doi: 10.18294/sc.2015.412.
The strengthening of pharmaceutical patent protection globally puts strains on access to essential medicines. According to the present paper, this process has led to the collision of the intellectual property rights adopted in the World Trade Organization (WTO) Trade-Related Aspects of Intellectual Property Rights (TRIPS) Agreement and the right to health stated in the International Covenant on Economic, Social and Cultural Rights (ICESCR). Several controversies disputed in the WTO illustrate the confrontation between countries with a powerful pharmaceutical industry and the interests of developing countries. It is concluded that the TRIPS-plus rules subscribed to by developing countries in free trade agreements which give the pharmaceutical patent holder more rights than those stipulated in the original TRIPS Agreement are incompatible with the obligations to provide access to essential medicines under the right to health of the ICESCR.
全球范围内加强药品专利保护给基本药物的获取带来了压力。根据本文,这一进程导致了世界贸易组织(WTO)《与贸易有关的知识产权协定》(TRIPS)所采用的知识产权与《经济、社会及文化权利国际公约》(ICESCR)中规定的健康权之间的冲突。WTO中存在的一些争议表明了制药业强大的国家与发展中国家利益之间的对抗。得出的结论是,发展中国家在自由贸易协定中所认可的超TRIPS规则给予药品专利持有人比原始TRIPS协定规定更多的权利,这与ICESCR健康权项下提供基本药物获取的义务不相容。